ArticleResearch square2026
The Association of Arsenic Metabolism and Blood Pressure: A Cross-Sectional Analysis in the MesoAmerican Nephropathy Occupational Study (MANOS).
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Growing evidence indicates that arsenic metabolism is associated with cardiometabolic outcomes but few studies have investigated the association of arsenic metabolism with blood pressure outcomes. Methods: We evaluated cross-sectional associations between urinary arsenic metabolites and blood pressure outcomes-systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure-among 393 participants in the MesoAmerican Nephropathy Occupational Study (MANOS) in El Salvador and Nicaragua. We applied three modeling approaches: (1) conventional models assessing each urinary arsenic species [inorganic arsenic (InAs), monomethylated arsenic (MMA), and dimethylated arsenic (DMA)] individually as a percentage of the sum of inorganic and methylated arsenic; (2) leave-one-out models evaluating the relative effects of two species while holding the third constant; and (3) principal components analysis (PCA) representing methylation steps of arsenic metabolism. Results: In conventional models adjusted for age, body mass index, worksite, pesticide use, smoking status, and water consumption, participants with higher vs. lower DMA% (>77.51% vs. ≤71.28% DMA over the sum of inorganic and methylated arsenic species) showed higher systolic blood pressure (β = 3.75 mmHg; 95% CI: 0.65, 6.85) and pulse pressure (β = 2.57 mmHg; 95% CI: 0.04, 5.10), while participants with higher vs. lower MMA% (>16.07% vs. ≤12.39%) showed lower systolic blood pressure (β = -3.70 mmHg; 95% CI: -6.86, -0.55) and pulse pressure (β = -2.76 mmHg; 95% CI: -5.33, -0.19). In leave-one-out models, higher DMA% (>77.51% vs. <71.28%) as a result of lower MMA%, was associated with higher systolic blood pressure (β = 7.24 mmHg; 95% CI: 2.25, 12.2), pulse pressure (β = 5.29 mmHg; 95% CI: 1.22, 9.36), and mean arterial pressure (β = 3.71 mmHg; 95% CI: -0.08, 7.50). PCA results supported these findings. The second methylation step from MMA to DMA was associated with higher systolic blood pressure (β = 0.93 mmHg; 95% CI: 0.11, 1.75) and pulse pressure (β = 0.74 mmHg; 95% CI: 0.07, 1.40). Conclusions: Our findings suggest that biomarkers of efficient methylation of inorganic arsenic to DMA are associated with higher blood pressure compared to partial methylation to MMA, highlighting the importance of arsenic metabolism profiles in cardiovascular risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.